Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK study of WD-1603 in healthy volunteers
NCT04553978Phase 1Unknown
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, randomised, open-label trial of WD-1603 in Parkinson's disease (PD), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 2 and Area Under the Curve at Day 2. Status: unknown.
02
Drugs
WD-1603
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04553978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553978.